HLA-DR AND HLA-DQ ARE NOT MARKERS FOR RAPID DISEASE PROGRESSION IN PRIMARY SCLEROSING CHOLANGITIS

被引:77
作者
OLERUP, O
OLSSON, R
HULTCRANTZ, R
BROOME, U
机构
[1] KAROLINSKA INST, HUDDINGE HOSP, NOVUM, CTR BIOTECHNOL, HUDDINGE, SWEDEN
[2] KAROLINSKA INST, HUDDINGE HOSP, DEPT CLIN IMMUNOL, HUDDINGE, SWEDEN
[3] KAROLINSKA INST, HUDDINGE HOSP, DEPT MED, HUDDINGE, SWEDEN
[4] SAHLGRENS UNIV HOSP, DEPT MED, GOTHENBURG, SWEDEN
[5] KAROLINSKA HOSP, DEPT MED, S-10401 STOCKHOLM, SWEDEN
关键词
D O I
10.1016/0016-5085(95)90463-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The association between primary sclerosing cholangitis (PSC) and the HLA haplotype A1, B8, DR3, DQ2 is well established. During the last few years, several additional HLA associations have been suggested in PSC. Furthermore, two different HLA-DR specificities have been reported to be markers for rapid disease progression. Our aim was to critically evaluate all of the current and as yet mostly unconfirmed HLA class II issues in PSC. Methods: Seventy-five Swedish patients with PSC were HLA-DR and HLA-DQ genotyped. Results: Of the recently described HLA associations in PSC, the association with the DRB1*1301, DQA1*0103, DQB1*0603 haplotype was decisively confirmed, whereas the DRB1*04 specificity was only slightly underrepresented and the frequency of DR2 was neutral. The association with codon 38 of DRB genes was secondary to the DRB3*0101 association. HLA-DR and HLA-DQ alleles were not found to be markers for disease progression. Conclusions: The HLA-associated genetic susceptibility to PSC cannot be attributed to specific amino acid positions of the DR beta chains. The highly discrepant results obtained in two previously reported studies and the present investigation indicate that HLA class II alleles are not markers for a more aggressive clinical course in PSC.
引用
收藏
页码:870 / 878
页数:9
相关论文
共 38 条
[1]   A DNA-RFLP TYPING SYSTEM THAT POSITIVELY IDENTIFIES SEROLOGICALLY WELL-DEFINED AND ILL-DEFINED HLA-DR AND DQ ALLELES, INCLUDING DRW10 [J].
BIDWELL, JL ;
BIDWELL, EA ;
SAVAGE, DA ;
MIDDLETON, D ;
KLOUDA, PT ;
BRADLEY, BA .
TRANSPLANTATION, 1988, 45 (03) :640-646
[2]   NOMENCLATURE FOR FACTORS OF THE HLA SYSTEM, 1991 [J].
BODMER, JG ;
MARSH, SGE ;
ALBERT, ED ;
BODMER, WF ;
DUPONT, B ;
ERLICH, HA ;
MACH, B ;
MAYR, WR ;
PARHAM, P ;
SASAZUKI, T ;
SCHREUDER, GMT ;
STROMINGER, JL ;
SVEJGAARD, A ;
TERASAKI, PI .
TISSUE ANTIGENS, 1992, 39 (04) :161-173
[3]  
BREWERTON DA, 1973, LANCET, V1, P904
[4]   HLA-DR-DQ HAPLOTYPES DEFINED BY RESTRICTION FRAGMENT ANALYSIS - CORRELATION TO SEROLOGY [J].
CARLSSON, B ;
WALLIN, J ;
BOHME, J ;
MOLLER, E .
HUMAN IMMUNOLOGY, 1987, 20 (02) :95-113
[5]  
CHAPMAN RWG, 1989, DIGEST DIS SCI, V26, P778
[6]   DUAL ASSOCIATION OF HLA DR2 AND DR3 WITH PRIMARY SCLEROSING CHOLANGITIS [J].
DONALDSON, PT ;
FARRANT, JM ;
WILKINSON, ML ;
HAYLLAR, K ;
PORTMANN, BC ;
WILLIAMS, R .
HEPATOLOGY, 1991, 13 (01) :129-133
[7]   AN EPIDEMIOLOGICAL STUDY OF ULCERATIVE COLITIS AND REGIONAL ENTERITIS IN OXFORD AREA [J].
EVANS, JG ;
ACHESON, ED .
GUT, 1965, 6 (04) :311-&
[8]   AMINO-ACID SUBSTITUTIONS AT POSITION-38 OF THE DR-BETA POLYPEPTIDE CONFER SUSCEPTIBILITY TO AND PROTECTION FROM PRIMARY SCLEROSING CHOLANGITIS [J].
FARRANT, JM ;
DOHERTY, DG ;
DONALDSON, PT ;
VAUGHAN, RW ;
HAYLLAR, KM ;
WELSH, KI ;
EDDLESTON, ALWF ;
WILLIAMS, R .
HEPATOLOGY, 1992, 16 (02) :390-395
[9]   THE SHARED EPITOPE HYPOTHESIS - AN APPROACH TO UNDERSTANDING THE MOLECULAR-GENETICS OF SUSCEPTIBILITY TO RHEUMATOID-ARTHRITIS [J].
GREGERSEN, PK ;
SILVER, J ;
WINCHESTER, RJ .
ARTHRITIS AND RHEUMATISM, 1987, 30 (11) :1205-1213
[10]   ASSOCIATION OF PRIMARY SCLEROSING CHOLANGITIS WITH HLA-DRW52A [J].
GRUNNET, N ;
RASMUSSEN, HH ;
TAGEJENSEN, U ;
RASMUSSEN, SN .
TISSUE ANTIGENS, 1991, 38 (03) :133-136